LAUSR

Hollow‐structured nanomaterials (HSNMs) have attracted increased interest in biomedical fields, owing to their excellent potential as drug delivery systems (DDSs) for clinical applications. Among HSNMs, hollow multi‐shelled structures (HoMSs) exhibit properties such as high loading capacity, sequential drug release, and multi‐functionalized modification and represent a new class of nanoplatforms for clinical applications. The remarkable properties of HoMS‐based DDS can simultaneously satisfy and enhance DDSs for delivering small molecular drugs (e.g., antibiotics, chemotherapy drugs, and imaging agents) and macromolecular drugs (e.g., protein/peptide‐ and nucleic acid‐based drugs). First, the latest research advances in delivering small molecular drugs are summarized and highlight the inherent advantages of HoMS‐based DDSs for small molecular drug targeting, combining continuous therapeutic drug delivery and theranostics to optimize the clinical benefit. Meanwhile, the macromolecular drugs DDSs are in the initial development stage and currently offer limited delivery modes. There is a growing need to analyze the deficiency of other HSNMs and integrate the advantages of HSNMs, providing solutions for the safe, stable, and cascade delivery of macromolecular drugs to meet vast treatment requirements. Therefore, the latest advances in HoMS‐based DDSs are comprehensively reviewed, mainly focusing on the characteristics, research progress by drug category, and future research prospects.